Antoniu Octavian Petris

Prof. Dr. Antoniu Octavian Petris

University of Medicine and Pharmacy " Grigore T. Popa", iasi, Romania
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2014 in European Heart Journal
Verified
Journal Article
Open access
PDF file
JZJose Luis Zamorano
Jose Luis Zamorano
SAStephan Achenbach
Stephan Achenbach
HBHelmut Baumgartner
Helmut Baumgartner
JBJeroen J. Bax
Jeroen J. Bax
HBHéctor Bueno
Héctor Bueno
DRDocument Reviewers
Document Reviewers
Guidelines summarize and evaluate all available evidence at the time of the writing process, on a particular issue with the aim of assisting health professionals in selecting the best management strategies for an individual patient, with a given condition, taking into account the impact on outcome, as well as the risk-benefit-ratio of particular diagnostic or therapeutic means. Guidelines and recommendations should help the health professionals to make decisions in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

10 April 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
GMGuy Meyer
Guy Meyer
EVEric Vicaut
Eric Vicaut
TDThierry Danays
Thierry Danays
GAGiancarlo Agnelli
Giancarlo Agnelli
CBCecilia Becattini
Cecilia Becattini
SKStavros Konstantinides
Stavros Konstantinides
The role of fibrinolytic therapy in patients with intermediate-risk pulmonary embolism is controversial. In a randomized, double-blind trial, we compared tenecteplase plus heparin with placebo plus heparin in normotensive patients with intermediate-risk pulmonary embolism. Eligible patients had right ventricular dysfunction on echocardiography or computed tomography, as well as myocardial injury as indicated by a positive test for cardiac troponin I or troponin T. The primary outcome was death or hemodynamic decompensation (or collapse) within 7 days after randomization. The main safety outcomes were major extracranial bleeding and ischemic or hemorrhagic stroke within 7 days after randomization. Of 1006 patients who underwent randomization, 1005 were included in the intention-to-treat analysis. Death or hemodynamic decompensation occurred in 13 of 506 patients (2.6%) in the tenecteplase group as compared with 28 of 499 (5.6%) in the placebo group (odds ratio, 0.44; 95% confidence interval, 0.23 to 0.87; P=0.02). Between randomization and day 7, a total of 6 patients (1.2%) in the tenecteplase group and 9 (1.8%) in the placebo group died (P=0.42). Extracranial bleeding occurred in 32 patients (6.3%) in the tenecteplase group and 6 patients (1.2%) in the placebo group (P<0.001). Stroke occurred in 12 patients (2.4%) in the tenecteplase group and was hemorrhagic in 10 patients; 1 patient (0.2%) in the placebo group had a stroke, which was hemorrhagic (P=0.003). By day 30, a total of 12 patients (2.4%) in the tenecteplase group and 16 patients (3.2%) in the placebo group had died (P=0.42). In patients with intermediate-risk pulmonary embolism, fibrinolytic therapy prevented hemodynamic decompensation but increased the risk of major hemorrhage and stroke. (Funded by the Programme Hospitalier de Recherche Clinique in France and others; PEITHO EudraCT number, 2006-005328-18; ClinicalTrials.gov number, NCT00639743.)

24 July 2022 in Life
Verified
Journal Article
Open access
PDF file
SLSabina Andreea Leancă
Sabina Andreea Leancă
DCDaniela Crișu
Daniela Crișu
Antoniu Octavian PetrisAntoniu Octavian Petris
Antoniu Octavian Petris
IAIrina Afrăsânie
Irina Afrăsânie
AGAntonia Genes
Antonia Genes
Irina Iuliana COSTACHE-ENACHEIrina Iuliana COSTACHE-ENACHE
Irina Iuliana COSTACHE-ENACHE
Myocardial infarction (MI) is the leading cause of death and morbidity worldwide, with an incidence relatively high in developed countries and rapidly growing in developing countries. The most common cause of MI is the rupture of an atherosclerotic plaque with subsequent thrombotic occlusion in the coronary circulation. This causes cardiomyocyte death and myocardial necrosis, with subsequent inflammation and fibrosis. Current therapies aim to restore coronary flow by thrombus dissolution with pharmaceutical treatment and/or intravascular stent implantation and to counteract neurohormonal activation. Despite these therapies, the injury caused by myocardial ischemia leads to left ventricular remodeling; this process involves changes in cardiac geometry, dimension and function and eventually progression to heart failure (HF). This review describes the pathophysiological mechanism that leads to cardiac remodeling and the therapeutic strategies with a role in slowing the progression of remodeling and improving cardiac structure and function.

21 January 2016 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
MKMarcin Koć
Marcin Koć
MKMaciej Kostrubiec
Maciej Kostrubiec
WEWaldemar Elikowski
Waldemar Elikowski
NMNicolas Meneveau
Nicolas Meneveau
MLMareike Lankeit
Mareike Lankeit
RIRiHTER Investigators
RiHTER Investigators
Our aim was the assessment of the prognostic significance of right heart thrombi (RiHT) and their characteristics in pulmonary embolism in relation to established prognostic factors.138 patients (69 females) aged (mean±sd) 62±19 years with RiHT were included into a multicenter registry. A control group of 276 patients without RiHT was created by propensity scoring from a cohort of 963 contemporary patients. The primary end-point was 30-day pulmonary embolism-related mortality; the secondary end-point included 30-day all-cause mortality. In RiHT patients, pulmonary embolism mortality was higher in 31 patients with systolic blood pressure <90 mmHg than in 107 normotensives (42%versus12%, p=0.0002) and was higher in the 83 normotensives with right ventricular dysfunction (RVD) than in the 24 normotensives without RVD (16%versus0%, p=0.038). In multivariable analysis the simplified Pulmonary Embolism Severity Index predicted mortality (hazard ratio 2.43, 95% CI 1.58–3.73; p<0.0001), while RiHT characteristics did not. Patients with RiHT had higher pulmonary embolism mortality than controls (19%versus8%, p=0.003), especially normotensive patients with RVD (16%versus7%, p=0.02).30-day mortality in patients with RiHT is related to haemodynamic consequences of pulmonary embolism and not to RiHT characteristics. However, patients with RiHT and pulmonary embolism resulting in RVD seem to have worse prognosis than propensity score-matched controls.

3 August 2022 in Life
Verified
Journal Article
Open access
PDF file
VSVictorita Sorodoc
Victorita Sorodoc
OSOana Sirbu
Oana Sirbu
CLCatalina Lionte
Catalina Lionte
RHRaluca Ecaterina Haliga
Raluca Ecaterina Haliga
ASAlexandra Stoica
Alexandra Stoica
LSLaurentiu Sorodoc
Laurentiu Sorodoc
In cancer survivors, cardiac dysfunction is the main cause of mortality. Cardiotoxicity represents a decline in cardiac function associated with cancer therapy, and the risk factors include smoking, dyslipidemia, an age of over 60 years, obesity, and a history of coronary artery disease, diabetes, atrial fibrillation, or heart failure. Troponin is a biomarker that is widely used in the detection of acute coronary syndromes. It has a high specificity, although it is not exclusively associated with myocardial ischemia. The aim of this paper is to summarize published studies and to establish the role of troponin assays in the diagnosis of cardiotoxicity associated with various chemotherapeutic agents. Troponin has been shown to be a significant biomarker in the diagnosis of the cardiac dysfunction associated with several types of chemotherapeutic drugs: anthracyclines, anti-human epidermal growth factor receptor 2 treatment, and anti-vascular endothelial growth factor therapy. Based on the data available at this moment, troponin is useful for baseline risk assessment, the diagnosis of cardiotoxicity, and as a guide for the initiation of cardioprotective treatment. There are currently clear regulations regarding the timing of troponin surveillance depending on the patient’s risk of cardiotoxicity and the type of medication administered, but data on the cut-off values of this biomarker are still under investigation.

26 January 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
Radu MIFTODERadu MIFTODE
Radu MIFTODE
Antoniu Octavian PetrisAntoniu Octavian Petris
Antoniu Octavian Petris
VAViviana ONOFREI AURSULESEI
Viviana ONOFREI AURSULESEI
CCCorina Cianga
Corina Cianga
Irina Iuliana COSTACHE-ENACHEIrina Iuliana COSTACHE-ENACHE
Irina Iuliana COSTACHE-ENACHE
Ionela Lacramioara SerbanIonela Lacramioara Serban
Ionela Lacramioara Serban
The increasing incidence of coronavirus disease 19 (COVID-19) and its polymorphic clinical manifestations due to local and systemic inflammation represent a high burden for many public health systems. Multiple evidence revealed the interdependence between the presence of cardiovascular comorbidities and a severe course of COVID-19, with heart failure (HF) being incriminated as an independent predictor of mortality. Suppression of tumorigenicity-2 ST2 has emerged as one of the most promising biomarkers in assessing the evolution and prognosis of patients with HF. The uniqueness of ST2 is determined by its structural particularities. Its transmembrane isoform exerts cardioprotective effects, while the soluble isoform (sST2), which is detectable in serum, is associated with myocardial fibrosis and poor outcome in patients with HF. Some recent data also suggested the potential role of sST2 as a marker of inflammation, while other studies highlighted it as a valuable prognostic factor in patients with COVID-19. In this review, we summarized the pathways by which sST2 is related to myocardial injury and its connection to the severity of inflammation in patients with COVID-19. Also, we reviewed possible perspectives of using it as a dual cardio-inflammatory biomarker, for both early diagnosis, risk stratification and prognosis assessment of patients with concomitant HF and COVID-19.